Fidelity Investments’s Candel Therapeutics CADL Stock Holding History
Bought
Maintained
Sold
Other funds holding CADL
ACA
SVCM
Fidelity Investments's CADL Position: Q3 2026 in Review
Fidelity Investments increased its Candel Therapeutics (CADL) stake by 5.3% in Q3 2026, buying an estimated $6.43M and bringing the position to 11,570,386 shares worth $121M. The position accounts for 0.01% of the portfolio, ranked #1139.
Fidelity Investments first reported a position in CADL in Q3 2021 and has held it in 19 quarters since. 141 funds tracked by Wall St. Rank hold CADL as of Q3 2026.
- Fidelity Investments held 11,570,386 shares of Candel Therapeutics worth $121M as of Q3 2026.
- Fidelity Investments bought 579,851 Candel Therapeutics shares in Q3 2026, an estimated $6.43M.
- Candel Therapeutics made up 0.01% of Fidelity Investments's portfolio in Q3 2026, its #1139 holding.
- Fidelity Investments first reported a position in Candel Therapeutics in Q3 2021 and has held it in 19 quarters since.
- 141 funds tracked by Wall St. Rank held Candel Therapeutics as of Q3 2026.
Based on Fidelity Investments's 13F filing for Q3 2026, filed 10 Nov 2026.